HomeSample Page

Balanced News: Sample Page Title

Our 'quick read' news summary

Shares of ProKidney Corp. PROK, +9.57% rallied about 29% in premarket trading on Wednesday, the day after the company said preliminary data from a Phase 2 study found that the company’s investigational renal autologous cell therapy treatment can delay the need for dialysis in some patients with chronic kidney disease. The study was published Jan. 4 in the journal Blood Purification; the company issued a news release about the study on Tuesday. ProKidney’s stock is down 22.3% for the past year, while the S&P 500 SPX, +0.70% has declined 16.1%.

Read different perspectives from these news sources

Searching for related articles, please check back here later!

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

More top reads from Balanced News Summary

Do you agree with this post's rating?
0
(0)
- Advertisment -
- Advertisment -